InvestorsHub Logo
Followers 789
Posts 118230
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 1102

Wednesday, 02/08/2023 7:50:17 AM

Wednesday, February 08, 2023 7:50:17 AM

Post# of 1161
Bayer enrolls first phase-3 patients for FXIa inhibitor, Asundexian:

• The OCEANIC program will investigate the efficacy and safety of asundexian (BAY2433334) in the prevention of stroke in patients with atrial fibrillation and also patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA)
• OCEANIC-AF and OCEANIC-STROKE are expected to enroll more than 27,000 patients in over 40 countries

Bayer’s competition in this arena is BMY/JNJ’s Milvexian (#msg-169818942, #msg-169841711), which is awaiting the start of phase-3.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News